METHOD FOR ALLEVIATING TOBACCO OR NICOTINE WITHDRAWAL SYMPTOMS

Abstract

The present disclosure provides a method for alleviating or suppressing tobacco or nicotine associated withdrawal symptoms and ease smoking cessation in individuals who wish to quit or decrease smoking tobacco or nicotine comprising the use of probiotic microorganisms.

Claims

1. A composition comprising at least one bacterial strain of a Lactobacillus species and an acceptable carrier for use in alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

2. The composition for use according to claim 1, wherein the at least one bacterial strain of a Lactobacillus species is a L. rhamnosus species.

3. The composition for use according to claim 2, wherein the at least one bacterial strain of the L. rhamnosus species is selected from the group consisting of L. rhamnosus R0011 (LHS), L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS), and L. rhamnosus R1039 (LHS).

4. The composition for use according to claim 3, wherein the at least one bacterial strain of the L. rhamnosus species is L. rhamnosus R0011 (LHS).

5. The composition for use according to any one of claims 1-4 further comprising at least one bacterial strain of a Bifidobacterium species.

6. The composition for use according to claim 5, wherein the at least one bacterial strain of a Bifidobacterium species is a B. longum species or a B. bifidum species.

7. The composition for use according to claim 6, wherein the at least one bacterial strain of a Bifidobacterium species is a B. longum species.

8. The composition for use according to claim 6, wherein the at least one bacterial strain of a Bifidobacterium species is a B. bifidum species.

9. The composition for use according to any one of claims 5-8, wherein the Lactobacillus species or strains and the Bifidobacterium species or strains are present in a mutual weight ratio of between about 100:1 to about 1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

10. The composition for use according to claim 9, wherein the bacterial species or strains are present in a mutual weight ratio of about 4:1 of Lactobacillus species or strains to Bifidobacterium species or strains.

11. The composition for use according to claim 5, comprising at least one bacterial strain of the B. longum species and at least one bacterial strain of the B. bifidum species.

12. The composition for use according to any one of claims 6-11, wherein the at least one bacterial strain of the B. longum species is selected from the group consisting of B. longum R0175 (LHS) and B. longum HA-135 (LHS).

13. The composition for use according to claim 12, wherein the at least one bacterial strain of the B. longum species is B. longum R0175 (LHS).

14. The composition for use according to any one of claims 6-13, wherein the at least one bacterial strain of the B. bifidum species is selected from the group consisting of B. bifidum R0071 (LHS) or B. bifidum HA-132 (LHS).

15. The composition for use according to claim 14, wherein the at least one bacterial strain of the B. bifidum species is B. bifidum R0071 (LHS).

16. The composition for use according to any one of claims 5-15, wherein said composition comprises at least one L. rhamnosus R0011 (LHS) strain and at least one B. longum R0175 (LHS) strain.

17. The composition for use according to any one of claims 5-15, wherein said composition comprises at least one L. rhamnosus R0011 (LHS) strain and at least one B. bifidum R0071 (LHS) strain.

18. The composition for use according to claim 11, wherein said composition comprises at least one L. rhamnosus R0011 (LHS) strain, at least one B. longum R0175 (LHS) strain, and at least B. bifidum R0071 (LHS) strain.

19. The composition for use according to any one of claims 1-18, wherein said composition is to be used in combination with a nicotine replacement therapy, optionally wherein said nicotine replacement therapy is a gum, a transdermal patch, a nasal spray, an inhaler, an oral spray or a sublingual tablets/lozenges.

20. The composition for use according to any one of claims 1-19, wherein the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine comprise depression, irritability, anxiety, restlessness, hunger, lack of concentration, insomnia, nervous tremor, light-headedness or craving for tobacco or nicotine.

21. The composition for use according to any one of claims 1-20, wherein the at least one bacterial strain of the Lactobacillus species, the at least one bacterial strain of the Bifidobacterium species, or a mixture thereof are for use at a dosage of from about 110.sup.5 to 110.sup.12 cfu total bacteria per dose, from about 110.sup.6 to 110.sup.11 cfu total bacteria per dose, from about 110.sup.7 to 110.sup.10 cfu total bacteria per dose, or from about 110.sup.8 to 110.sup.10 cfu total bacteria per dose.

22. The composition for use according to any one of claims 1-21, wherein said composition is provided in the form of a freeze-dried power, a tablet, a capsule, a pill, a suspension, an emulsion, a liquid preparation, a gel or a syrup.

23. The composition for use according to any one of claims 1-21, wherein said composition is provided in the form of a milk product, a yogurt, a curd, a cheese, a fermented milk, a milk powder, a milk based fermented product, an ice-cream, a fermented cereal based product, a milk based powder, a beverage, a dressing, a meat product, a spread, a filling, a frosting, a chocolate, a confectionery, a baked good, a sauces, a soup, a fruit juice, or a coffee whitener.

24. A method of alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine comprising administering to an individual in need thereof a composition comprising a therapeutically effective amount of at least one bacterial strain of a Lactobacillus species.

25. The method of claim 24, wherein the composition comprising a therapeutically effective amount of at least one bacterial strain of a Lactobacillus species is as defined in any one of claims 1-23.

26. A method of formulating a composition for alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine, wherein said method comprises mixing at least one bacterial strain of a Lactobacillus species with an acceptable carrier to prepare said composition.

27. The method of claim 26, wherein said composition is as defined in any one of claims 1-23.

28. Use of a composition comprising at least one bacterial strain of a Lactobacillus species and an acceptable carrier for the manufacture of a medicament for alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

29. A non-therapeutic use of at least one bacterial strain of a Lactobacillus species, at least one bacterial strain of a Bifidobacterium species, or a mixture thereof, for the preparation of a composition for alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

30. The use of claim 28 or 29, wherein said composition is as defined in any one of claims 1-23.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Having thus generally described the nature of the invention, reference will now be made to the accompanying drawings, showing by way of illustration, a preferred embodiment thereof, and in which:

[0036] FIG. 1 illustrates C. elegans behavioral toxicity following 24 hours exposure to nicotine and tobacco extract. During the assay, the worms were also exposed to probiotic bacteria.

[0037] FIG. 2 is a schematic representation of the percentage of participants who self-reported as abstinent but continued smoking, participants who reported smoking, and participants who were truly abstinent as determined by a carbon monoxide (CO) breath test (between week 2 and week 4).

DETAILED DESCRIPTION

[0038] It has been surprisingly discovered that the use of the probiotic cultures of the genus Bifidobacterium, Lactobacillus, or a mixture thereof is beneficial in assisting to alleviate or suppress one or more withdrawal symptoms which afflict individuals who are trying to eliminate or decrease their use of tobacco or nicotine.

[0039] As is apparent from the examples below, it was found that the use of the probiotics Bifidobacterium, Lactobacillus or a mixture thereof proves to be especially useful for palliating tobacco or nicotine withdrawal (or partial withdrawal) symptoms or facilitating smoking cessation. The method of the present disclosure may be used in conjunction with a nicotine replacement therapy (NRT).

[0040] The common symptoms in individuals experiencing tobacco or nicotine withdrawal include, for example, depression, irritability, anxiety, restlessness, hunger, lack of concentration, insomnia, nervous tremor, light-headedness, and the craving for tobacco or nicotine. In addition to the difficulty related to cessation of smoking, common side effect that individuals experience when attempting to quit smoking is a substantial increase in appetite because they are craving food as a response to their anxiety. This increased hunger results in undesirable increases in body weight.

[0041] The term promoting smoking cessation as used herein refers to helping an individual to quit or reduce tobacco smoking or to quit or reduce use of tobacco products. The term promoting smoking cessation also refers to a reduction in a number of tobacco products smoked by an individual treated with the method of the present disclosure. Furthermore, the term promoting smoking cessation refers to alleviate, reduce, control, prevent, suppress or treat various symptoms associated with tobacco or nicotine withdrawal (including cravings for food) and/or to decrease craving for tobacco products or nicotine. The terms alleviate, reduce or prevent are intended to refer to any degree of reduction of the symptoms suffered by an individual.

[0042] The term tobacco or nicotine withdrawal symptoms as used herein refers to any physical or psychological reaction relating to breaking the habit of smoking tobacco or nicotine or using any tobacco product or decreasing the frequency or intensity of smoking tobacco or using any tobacco product.

[0043] The term effective amount as used herein is an amount of probiotics which is sufficient to produce the expected effect.

[0044] The term probiotic microorganism as used herein refers to a live microorganism which, when administered in adequate amounts, confers a health benefit to the host. A probiotic must fulfil several requirements related to lack of toxicity, viability, adhesion and beneficial effects.

[0045] As used herein, the term Bifidobacterium refers to members of the genus Bifidobacterium. These bacteria are Gram-positive anaerobic bacteria that are one of the major strains of bacteria present in the gastrointestinal flora. Specific examples of Bifidobacterium species include, without limitation, B. bifidum, B. animalis subsp. lactis, B. breve, B. longum, or B. longum subsp. infantis. While it is not intended that the present disclosure be limited to any particular species of Bifidobacterium, exemplary species and strains of Bifidobacterium for the present disclosure includes, but are not limited to, the following well-known strains: B. bifidum HA-132 (sold by Lallemand Health Solutions (LHS)), B. bifidum R0071 (LHS), B. breve HA-129 (LHS), B. breve R0070 (LHS), B. infantis HA-116 (LHS), B. infantis R0033 (LHS), B. lactis HA-194 (LHS), B. longum HA-135 (LHS), B. longum R0175 (LHS), B. animalis subsp. lactis R0421 (LHS). In an embodiment, the Bifidobacterium is B. longum. In a particular embodiment, B. longum is B. longum R0175 (LHS). B. longum R0175 (LHS) is also referred to as B. longum susp. longum R0175, B. longum susp. longum Rosell-175, B. longum Rosell-175, and Rosell-175. These terms are used interchangeably herein. Alternatively, the Bifidobacterium can be B. bifidum. In particular, B. bifidum is B. bifidum R0071 (also referred to as B. bifidium Rosell-71 or Rosell-71). Other bacterial strains having a name including an R code, e.g. R0123, may be commercially known with respect to the name Rosen, e.g. Rosell-123. It is intended that the genus include species that have been reclassified (e.g., due to changes in the speciation of organisms as the result of genetic and other investigations) or renamed for marketing and/or other purposes.

[0046] As used herein, the term Lactobacillus refers to members of the genus Lactobacillus, in the family Lactobacillaceae. These bacteria are Gram-positive facultatively anaerobic bacteria that represent a major part of the bacterial group often referred to as lactic acid bacteria. Lactobacillus species include, without limitation, L. acidophilus, L. brevis, L. bulgaricus, L. casei, L. crispatus, L. delbrueckii, L. fermentum, L. gasseri, L. helveticus, L. lactis, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius or L. paracasei. While it is not intended that the present disclosure be limited to any particular species of Lactobacillus, exemplary species and strains of Lactobacillus for the present disclosure includes, but are not limited to, the following well-known strains: L. acidophilus HA-122 (LHS), L. acidophilus R0418 (LHS), L. brevis HA-112 (LHS), L. casei HA-108 (LHS), L. casei R0215 (LHS), L. delbrueckii bulgaricus HA-137 (LHS), L. fermentum HA-179 (LHS), L. helveticus HA-128 (LHS), L. helveticus HA-501 (LHS), L. helveticus R0052 (LHS), L. helveticus Lafti L10 R0419 (LHS), L. paracasei HA-196 (LHS), L. paracasei HA-274 (LHS), L. paracasei Lafti L26 R0422 (LHS), L. plantarum R0403 (LHS), L. plantarum R0202 (LHS), L. plantarum R1012 (LHS), L. reuteri HA-188 (LHS), L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0011 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS), L. rhamnosus R1039 (LHS), L. salivarius HA-118 (LHS), L. salivarius R0078 (LHS), L. bulgaricus R0440 (LHS) or L. lactis R1087 (LHS). In an embodiment, the Lactobacillus is L. rhamnosus. In a further embodiment, L. rhamnosus is L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0011 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS) or L. rhamnosus R1039 (LHS). In a particular embodiment, L. rhamnosus is L. rhamnosus R0011 (LHS) (interchangeably referred to as L. rhamnosus Rosell-11 or Rosell-11). It is intended that the genus include species that have been reclassified (e.g., due to changes in the speciation of organisms as the result of genetic and other investigations) or renamed for marketing and/or other purposes.

[0047] In an embodiment, one probiotic microorganism (e.g. a strain) of the present disclosure may be used alone or in combination with or in conjunction with one or more different probiotic microorganisms. As used herein, the term in combination with or in conjunction with means together, substantially simultaneously or sequentially. In an embodiment, a bacterium (e.g. a strain) of the genus Lactobacillus or Bifidobacterium can be used in combination or in conjunction with at least one bacterial strain from within the same species and not bacteria from any other species. In some embodiments, at least a bacterium (e.g. a strain) of the genus Lactobacillus or Bifidobacterium can be used in combination or in conjunction with more than one species from within the same genus and not bacteria from any other genus. In a particular embodiment, at least a bacterium (e.g. a strain) of the genus Bifidobacterium is used in combination or in conjunction with at least a bacterium (e.g. a strain) of the genus Lactobacillus. In a further embodiment, L. rhamnosus can be provided in combination with B. bifidum, B. longum or a mixture thereof. In an embodiment, L. rhamnosus can be L. rhamnosus R0011 (LHS). B. bifidum can be B. bifidum R0071. In a particular embodiment, B. longum is B. longum subsp. longum and can be, for example B. longum subsp. longum R0175 (LHS). It will be appreciated that the probiotics of the present disclosure may be combined with other suitable microorganisms (e.g. strains of probiotics bacteria) or yeasts.

[0048] Examples of suitable microorganisms are yeast such as Saccharomyces, and bacteria such as the genera Propionibacterium, Streptococcus, Enterococcus, Lactococcus, Bacillus, Pediococcus, Oenococcus or combination thereof. Saccharomyces species include, without limitation, S. cerevisiae or S. cerevisiae var. boulardii. Specific examples of suitable probiotic microorganisms are: Enterococcus faecium HA-127 (LHS), Enterococcus faecium R0026 (LHS), Lactococcus lactis subsp. lactis HA-136 (LHS), Lactococcus lactis R1058 (LHS), Streptococcus thermophilus HA-110 (LHS), Streptococcus thermophilus R0083 (LHS), Bacillus subtilis HA-124 (LHS), Bacillus subtilis R0179 (LHS), Propionibacterium freudenreichii HA-273 (LHS), Propionibacterium shermanii HA-182 (LHS) or Pediococcus acidilacticii R1001 (LHS). In some embodiments, multiple strains of the same bacteria species are utilized in combination.

[0049] The effective amount of colony forming units (cfu) for each strain in the composition will be determined by the skilled in the art and will depend upon the final formulation. The term colony forming unit is defined herein as number of bacterial cells as revealed by microbiological counts on agar plates. For instance, in an embodiment, the total probiotic is provided in an amount of from about 10.sup.5 to 10.sup.12 colony forming units (cfu) per dose, from about 10.sup.6 to 10.sup.11 cfu per dose, from about 10.sup.7 to 10.sup.10 cfu per dose or from about 10.sup.8 to 10.sup.10 cfu per dose. In yet another embodiment, the probiotic is provided in an amount greater than about 1.010.sup.9 cfu total probiotic per dose. In some embodiments, the individual is administered greater than 5.010.sup.9 cfu total probiotic per dose. However, it is not intended that the present disclosure be limited to a specific dosage as it is contemplated that dosages of total probiotic will vary depending upon a number of factors such as the identity and number of individual probiotic strains employed, the subject being treated, the nature of the symptoms suffered by the subject that is to be treated, the general health of the subject, and the form in which the composition is administered.

[0050] When a bacterium of the genus Bifidobacterium or a bacterium of the genus Lactobacillus is used in combination with one different probiotic microorganism (e.g. a different strain), the bacteria may be present in any ratio capable of achieving the desired effects of the disclosure described herein. Typically, the bacterial species or strains constituting the probiotic mixture are present in a mutual weight ratio of between about 100:1 to about 1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

[0051] For example, when a bacterium of the genus Bifidobacterium is used in combination with a bacterium of the genus Lactobacillus, the bacteria may be present in any ratio capable of achieving the desired effects of the disclosure described herein. Typically, the Lactobacillus to Bifidobacterium are present in a mutual weight ratio of between about 100:1 to about 1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

[0052] More particularly, when B. longum is used in combination with L. rhamnosus, the bacteria species or strains constituting the mixture are present in a Lactobacillus to Bifidobacterium mutual weight ratio of between about 100:1 to about 1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

[0053] In another example, when B. bifidum is used in combination with L. rhamnosus, the bacteria species or strains constituting the mixture are present in a Lactobacillus to Bifidobacterium mutual weight ratio of between about 100:1 to about 1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

[0054] In an embodiment, when at least three or more probiotic strains are used in combination, the weight ratio of individual strains constituting the mixture is from about 100:1 to about:1:100, between about 50:1 to about 1:50, between about 20:1 to about 1:20, between about 10:1 to about 1:10, between about 9:1 to about 1:9, between about 8:1 to about 1:8, between about 7:1 to about 1:7, between about 6:1 to about 1:6, between about 5:1 to about 1:5, between about 4:1 to about 1:4, between about 3:1 to about 1:3, between about 2:1 to about 1:2 or 1:1.

[0055] While it is possible to administer the probiotics of the present disclosure alone, they are typically administered on or in a support as part of a product, in particular as a component of a food product, a dietary supplement, medicament or a pharmaceutical formulation. These products typically contain additional components, acceptable excipients, carriers or adequate additives well known to those skilled in the art. The term acceptable excipients and carriers as used herein pertains to those that are compatible with the other ingredients in the formulation and biologically acceptable. In a particular embodiment, the products additionally contain one or more further active agents. In another embodiment, the additional active agent or agents are other probiotic bacteria or yeasts which are not antagonist to the strains forming the composition of the present disclosure. Depending on the formulation, the strains may be added as purified bacteria, as a bacterial culture, as part of a bacterial culture, as a bacterial culture which has been post-treated. Prebiotics could be also added. The food product, the dietary supplement or the pharmaceutical formulation may be prepared in any suitable form which does not negatively affect the bioavailability of the strains forming the composition and is within the scope of ordinary persons skilled in the art.

[0056] For example, the probiotic composition of the present disclosure can be formulated to be administered orally in the form of freeze-dried power, tablet, capsules, pills, suspension, lozenge, emulsion, liquid preparations, gel, syrup etc.

[0057] The probiotic composition of the present disclosure can be used as an ingredient in food products such as milk products, yogurt, curd, cheese (e.g. quark, cream, processed, soft and hard), fermented milk, milk powder, milk based fermented product, ice-cream, a fermented cereal based product, milk based powder, a beverage, a dressing, meat products (e.g. liver paste, frankfurter and salami sausages or meat spreads), spreads, fillings, frostings, chocolate, confectionery (e.g. caramel, candy, fondants or toffee), baked goods (cakes, pastries), sauces and soups, fruit juices or coffee whiteners.

[0058] The probiotic microorganisms are produced by cultivating the microorganisms in a suitable medium and under suitable conditions as known in the art. The probiotic microorganisms can be cultivated alone to form a pure culture, or as a mixed culture together with other microorganisms, or by cultivating probiotic microorganisms of different types separately and then combining them in the desired proportions. After cultivation until a predetermined CFU/g concentration is reached, the cell suspension is recovered and used as such or treated in the desired manner, for instance, by concentrating, spray drying, lyophilization, flatbed oven drying or freeze-drying, to be further employed in the preparation of composition and can be blend with a carrier medium. Sometimes the probiotic preparation is subjected to an immobilisation or encapsulation process in order to improve the shelf life. Several techniques for immobilisation or encapsulation of bacteria are known in the art.

[0059] The probiotic strains used in the present disclosure are in the form of viable cells. However, the probiotic strains of the present disclosure can also be in the form of non-viable cells such as killed cultures or compositions containing beneficial factors produced by the probiotics. This could include thermally killed micro-organisms or micro-organisms killed by exposure to altered pH, sonication, radiation or subjection to pressure. With non-viable cells product preparation is simpler, cells may be incorporated easily into commercial products and storage requirements are much less limited than viable cells.

[0060] In accordance with the present disclosure, probiotic compositions will normally be administered so that a symptom-ameliorating effective daily dose is received by the subject. The daily dose may be given in divided doses as necessary, the precise amount of the compound or agent received and the route of administration depending on the general health of the subject being treated according to principles known in the art. A typical dosage regime is once, twice or three daily.

[0061] The probiotic composition of the present disclosure can be used in conjunction with a nicotine replacement therapy such as, but not limited to, gum, nicotine transdermal patches, nasal spray, inhaler, oral spray or sublingual tablets/lozenges. In an embodiment, the nicotine replacement therapy is nicotine transdermal patches.

[0062] The word comprising in the claims may be replaced by consisting essentially of or with consisting of, according to standard practice in patent law.

[0063] The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLES

Example 1: Effect of B. bifidum, B. longum and L. rhamnosus on Caenorhabditis elegans Model Submitted to Nicotine and Tobacco Extract

[0064] Objective:

[0065] The objective of this study was to evaluate the effect of B. bifidum, B. longum, L. rhamnosus and combination thereof on the behavior of C. elegans submitted to nicotine and tobacco extract.

[0066] Cultures of B. bifidum, B. longum and L. rhamnosus:

[0067] L. rhamnosus R0011 strain was grown anaerobically in MRS broth at 37 C. overnight. B. longum R0175 was grown anaerobically in MRS broth supplemented with 0.05% cysteine at 37 C. overnight.

[0068] Overnight cultures of strains R0011 and R0175 along with 1 g of lyophilized powder of B. bifidum R0071 were washed once with M9 buffer and resuspended in 10 ml of M9 buffer after centrifugation for 10 minutes at 4000 rpm. The number of viable bacterial cells used in the experiment was analyzed on the flow cytometer and the fluorescent signal from the bacteria was detected and a count per unit volume was determined and adjusted at a concentration of 210.sup.8 cfu/ml.

[0069] The effect of each bacterial strain was tested alone and in combination. L. rhamnosus R0011 and B. longum R0175 were blended in a ratio of 80:20. L. rhamnosus R0011 and B. bifidum R0071 were blended in a ratio of 80:20. A third blend was tested and combined L. rhamnosus R0011, B. longum R0175 and B. bifidum R0071 in a ratio of 80:10:10.

[0070] Synchronization of C. elegans:

[0071] Experiments were carried out with the wild type strain N2 of C. elegans. Worms were synchronized by isolating eggs from gravid adults, collecting the eggs in M9 buffer, hatching the eggs overnight in NGM plates and sterilely isolating L1-stage worms with M9 buffer. The L1-stage worms were transferred to NGM (Nematode Growth Medium) plates inoculated with Escherichia coli strain OP50 and incubated for four days at 15 C. to reach adulthood.

[0072] Preparation of the Nicotine and Tobacco Extract:

[0073] Nicotine ditartrate dihydrate 100 mM (Acros) was diluted in M9 buffer to a final concentration of 6.2 mM. Similarly, a natural tobacco extract (ABT #6079, Advanced Biotech) was diluted in M9 buffer to a final concentration of 6.2 mM.

[0074] Assay:

[0075] Adult worms were washed in M9 buffer and 250 l of worm suspension was transferred to 24-well culture plates with or without nicotine (250 l if present) or tobacco extract (250 l if present) and with or without probiotic suspension (500 l if present). The probiotic suspension was added first to the wells followed by the nicotine or the tobacco extract. At least 40 worms were present per well. The plates were incubated at 20 C. for 24 hours. After incubation period, worm suspension in each well was washed three times in M9 buffer (centrifugation of four minutes at 1000 rpm). The worms were transferred in new 24-well culture plates containing 1 ml of agar 1% in each well. The worms were allowed to equilibrate for 45 minutes, and then the thrashing (swimming) was recorded using a Leica EC3 camera. The average thrashings per second were computed and then plotted for all of the probiotic strains and combinations of strains.

[0076] Results and Conclusion:

[0077] As shown in FIG. 1, millimolar exposures of nicotine induced a reversible paralysis to C. elegans. This is represented in the drop in performance of control worms incubated with no bacteria and challenged with pure nicotine compared to no challenge control. Co-incubation with L. rhamnosus R0011, B. longum R0175, combinations of L. rhamnosus R0011 with B. longum R0175, L. rhamnosus R0011 with B. bifidum R0071 and the combination of the three probiotic strains seemed to prevent the decrease in swimming speed induced by the exposure to nicotine ditartrate dihydrate (Acros). This could possibly be achieved by preventing the over-neuroexcitiation by nicotine and/or accelerating/aiding the recovery post exposure.

[0078] In addition to nicotine, the tobacco extract contain other constituents that were highly toxic to the worms and induced a greater paralysis/death (or decreased the thrashing and body bend) as compared to the assay performed with nicotine (FIG. 1). The results showed that L. rhamnosus R0011 alone, combinations of L. rhamnosus R0011 with B. longum R0175, L. rhamnosus R0011 with B. bifidum R0071 and the combination of the three probiotic strains attenuated the toxic effect of tobacco extract in C. elegans.

Example 2: Clinical Trial Assessing the Effectiveness of Two Probiotic Products During Nicotine Replacement Therapy for Managing Withdrawal Symptoms Associated with Smoking Cessation

[0079] Objective:

[0080] The objective of this clinical study was to evaluate the efficacy or potential of the probiotics B. bifidum, B. longum subsp. longum and L. rhamnosus during nicotine replacement therapy for managing withdrawal symptoms associated with smoking cessation.

[0081] Study Design:

[0082] The study was a double-blind, prospective, randomized, placebo controlled trial. The total study duration was 16 weeks. The randomization was kept blinded to the patient and the investigators.

[0083] Study Population:

[0084] Seventy-five healthy participants between 18 and 65 years of age, moderate or heavily smokers were selected for the trial. Moderate or heavily smokers are defined by a Fagerstrom score 5 and who smoke more than 10 cigarettes per day. Participants were also selected for their willingness to stop smoking, corresponding to a score of 6 or 7 to the Motivation To Stop Scale (MTSS) (Kotz et al., 2013). The MTSS is a one-item questionnaire with 7 possible choices, from 1 (lowest level of motivation to stop smoking) to level 7 (highest level of motivation to stop smoking). Moreover, the participants had to discontinue consumption of probiotic supplements and food containing added probiotics or and/or prebiotics (e.g. yoghourts, with live, active cultures or supplements).

[0085] The trial has one placebo control group (Group 1) and two experimental treatment groups (Group 2 and Group 3). Subjects are assigned to one of the following treatment groups:

[0086] Group 1: placebo

[0087] Group 2: probiotic product 1

[0088] Group 3: probiotic product 2

[0089] Test Products:

[0090] Probiotic product 1 (Lactobacillus rhamnosus R0011 and Bifidobacterium bifidum R0071):

[0091] The probiotic product 1 under investigation is a combination of Lactobacillus rhamnosus R0011 and Bifidobacterium bifidum R0071 under the form of freeze-dried bacteria standardized with potato starch and magnesium stearate. The concentration of total probiotic is 510.sup.9 CFU per capsule after 2 years at 25 C. The ratio of both bacteria is L. rhamnosus R0011: B. bifidum R0071 is 4:1 after 2 years at 25 C.

[0092] Probiotic product 2 (Lactobacillus rhamnosus R0011 and Bifidobacterium longum subsp. longum R0175):

[0093] The probiotic product 2 under investigation is a combination of L. rhamnosus R0011 and B. longum subsp. longum R0175, under the form of freeze-dried bacteria standardized with potato starch and magnesium stearate. The concentration of total probiotic is 510.sup.9 CFU per capsule after 2 years at 25 C. The ratio of both bacteria is L. rhamnosus R0011: B. longum subsp. longum R0175 4:1 after 2 years at 25 C.

[0094] The placebo contains potato starch and magnesium stearate. Probiotics in both combinations appear as a white powder with small beige specks inside a transparent capsule.

[0095] Treatment Administration and Procedure:

[0096] Participants were randomized in three groups receiving either one of the probiotic product or the placebo. It has been shown that withdrawal symptoms are important during the first days of tobacco abstinence. Therefore, at day 0 participants received the investigation product (IP) for 2 weeks before the quit day and beginning of NRT (at week 2), to increase the potential to detect effects on withdrawal symptoms. Nicotine patches (active ingredient: nicotine and non-medicinal ingredients: acrylate adhesive, aluminized polyester, silicone adhesive) were used as NRT. The probiotic supplementation was provided for 14 weeks, i.e. from DO to week 14 while the nicotine patches were provided for 10 weeks, i.e. from week 2 to week 12.

[0097] The three groups of participants were followed-up during 16 weeks. All participants had a study visit at Day 2 (Screening Visit), at DO, at week 2 (D14), at week 4 (D28), at week 12 (Day 84), at week 14 (Day 98) and a follow-up visit at week 16 (Day 112). One phone call was performed at week 8.

[0098] Participants were requested to complete a daily diary to assess compliance to IP and NRT, rate the number of cigarettes smoked, assess withdrawal symptoms (using MPSS), bowel movements and stool consistency, daily throughout the study. Evolution of anxiety and depression symptoms, nicotine addiction, body weight and food cravings were also be scored during the study.

[0099] Study Assessments:

[0100] During all the period of the study, participants were completing a daily report to rate their withdrawal symptoms using the mood and physical symptoms scale (MPSS) (Prapavessis et al. 2007; Javors et al. 2011; Coleman et al. 2012).

[0101] The MPSS is a 12-item scale which can be divided in 3 subscales (West, 2012): [0102] MPSS(M), assessing mood: depression, anxiety, irritability, restlessness, hunger, lack of concentration and sleep (insomnia). [0103] MPSS(C), assessing craving: urgency in terms of number of craving per day and strength of the craving. [0104] MPSS(P), assessing physical symptoms: sores in the mouth, constipation, cough/sore throat.

[0105] The MPSS(M) score, corresponding to the sum of the 7 items for the MPSS(M) subscale, was compared between groups, daily between week 2 and 4 (first 2 weeks of tobacco abstinence) and week 12 and 14 (first 2 weeks after the end of NRT), and weekly for the other weeks. For weekly comparisons, an average of daily scores was done for the respective weeks. The score was also compared in time within groups, using the baseline ratings as covariates.

[0106] Furthermore, the following tests were conducted:

[0107] Hospital Anxiety and Depression Scale (HADS). The HADS is a widely used patient self-rated scale with 14 questions (7 anxiety and 7 depression questions) that ranges from 0-42. The higher the score, the more pronounced the symptom. A score of 7 indicates an absence of a disorder; a score ranging from 8 to 10 indicates a probable case of anxiety or depression; and, a score of 11 indicates a definite case of anxiety or depression. The HADS questionnaire will be administered at each visit.

[0108] The Fagerstrom Test for Nicotine Dependence (FTND). The FTND assess the evolution of nicotine addiction using a validated self-questionnaire. The FTND was used to assess dependence. No standard cut-off for nicotine dependence has been defined, but the following has been suggested: 1-2=very low dependence; 3-4=low dependence; 5=medium dependence; 6-7=high dependence; 8-10=very high dependence (Fagerstrom et al., 1990).

[0109] Carbon monoxide levels in exhaled air. Carbon monoxide in exhaled air was measured in participants at each visit using a carbon monoxide monitor as an assessment of smoking cessation.

[0110] Salivary cotinine levels. Cotinine level monitoring can be used to provide an objective quantitative assessment of smoking status. Cotinine levels were determined in saliva samples by immunoassays. A participant was considered to be abstinent if the cotinine level measured in his saliva is less than 10 ng/ml (Prapavessis et al. 2007; Javors et al. 2011; Coleman et al. 2012).

[0111] Assessment of food cravings. Participants were asked to assess their food cravings weekly using the Questionnaire on Craving for Sweet or Rich Foods (QCSRF) (Toll et al., 2008). The QCSRF measures the intensity of craving for sweet or rich foods among smokers. The first question is about craving at this moment and the next 5 questions are related to the past week. All these six questions are rated from none at all to more than ever on a 7-point Likert scale. The 8 other questions assess current cravings using a 7-point Likert scale, from strongly disagree to strongly agree. The evolution of the body weight was assed and measured at each visit.

[0112] Bristol Stool Scale. The Bristol Stool Scale is seven-point scale measuring stool consistency in adults with functional gastrointestinal disorders. In order to assess the effect of probiotics and smoking cessation on daily bowel movement frequency, participants were asked daily to rate the consistency of each of their bowel movement using the Bristol Stool Scale.

[0113] Microbiome Analysis and Persistence of Strains. Stool samples were collected at week 0 and at the end of week 14. Changes in the microbiome composition of participants as well as persistence of the probiotic strains were determined by genotypic methods.

[0114] Results:

[0115] The scores between Group 1 (placebo1629), Group 2 (probiotic product 14682) and Group 3 (probiotic product 28213) were recorded between weeks 1-2 (Pre-Baselineprior to smoking cessation and beginning of NRT) until weeks 3-4 (NRT Therapyduring smoking cessation). The analysis of data of the Mood and Physical Symptoms Scale (MPSS(M)) showed that the participants taking the probiotic product 2 (Lactobacillus rhamnosus R0011 and Bifidobacterium longum subsp. longum R0175) had the lowest increase in withdrawal symptoms from pre-baseline to NRT therapy when compared to the placebo group (Table 1). More particularly, the use of probiotic product 2 resulted in a smaller overall difference in the withdrawal symptoms amongst all three groups. Although these results did not reach statistical significance (p=0.4478), they demonstrated that the probiotic product 2 have a greater efficacy in mitigating withdrawal symptoms. In conclusion, the probiotic product 2 reduced depression, anxiety, and stress and improved positive mood in a higher proportion.

TABLE-US-00001 TABLE 1 Changes in mean MPSS (M) Score for Smoking-Abstinent Participants by Treatment Group (F = 0.8752; p = 0.4478) Pre-Baseline NRT Therapy Correla- Difference Group (mean SD) (mean SD) tion ( SE) p-Value Placebo 10.66 1.88 12.31 2.05 0.99 1.65 0.13 0.0010 Probiotic 8.29 0.96 10.99 3.03 0.58 2.70 0.98 0.0327 product 1 Probiotic 11.66 4.59 12.68 4.21 0.88 1.03 0.74 0.2030 product 2

[0116] As illustrated in FIG. 2, both probiotic products improved smoking abstinence in participants between week 2 and week 4. FIG. 2 depicts the number and percentage of participants who self-reported as abstinent but continued smoking, participants who reported smoking, and participants who were truly abstinent as determined by a carbon monoxide (CO) breath test.

[0117] Furthermore, a CO breath test was conducted on the remaining seven participants in each of the three groups at end of the study (week 16) in order to determine the number of truly abstinent participants. The results shown in Table 2 indicated that both probiotic products had a greater proportion of truly abstinent participants compared to the placebo group. Probiotic product 2 was again the most effective in maintaining smoking abstinence.

[0118] Thus, it is contemplated that these probiotics (product 1: Lactobacillus rhamnosus R0011 and Bifidobacterium bifidum R0071 an product 2: Lactobacillus rhamnosus R0011 and Bifidobacterium longum subsp. longum R0175) will find use in the management of withdrawal symptoms associated with smoking cessation and in maintaining smoking abstinence.

TABLE-US-00002 TABLE 2 Smoking Cessation Status at week 16 Probiotic Probiotic product 1 product 2 R0011 + R0011 + R0071 R0175 Placebo Total (N = 26) (N = 25) (N = 24) (N = 75) Visit 6 CO con- n 7 7 7 21 (Week centration 16)- in exhaled End of air (ppm) study Non- 4 7 3 14 smoker (57.1%) (100.0%) (42.9%) (66.7%) (0-10 ppm) Smoker 3 0 (0.0%) 4 7 (>10 (42.9%) (57.1%) (33.3%) ppm)

[0119] The analysis of data of the Mood and Physical Symptoms Scale (MPSS(C)) assessing craving, shown in Table 3, demonstrated that the probiotic products 1 and 2 were effective in reducing tobacco cravings or the urge to smoke.

TABLE-US-00003 TABLE 3 Changes in mean MPSS (C) Score for Smoking-Abstinent Participants by Treatment Group (F = 0.2504; p = 0.7809) Pre- NRT Baseline Therapy Difference p- Group (mean SD) (mean SD) Correlation ( SD) Value Placebo 5.71 0.71 5.05 2.01 +0.62 0.66 1.72 0.4403 Probiotic 5.87 0.87 5.10 1.67 +0.84 0.77 1.06 0.0396 product 1 Probiotic 5.33 0.59 4.61 0.75 +0.52 0.72 0.66 0.0119 product 2

[0120] While the invention has been described in connection with specific embodiments thereof, it will be understood that the scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.

REFERENCES

[0121] Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical pharmacology and therapeutics. 2008; 83(4):531-41. [0122] Benowitz, N. L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009; 49:57-71. [0123] Coleman T, Cooper S, Thornton J G, Grainge M J, Watts K, Britton J, et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. The New England journal of medicine. 2012; 366(9):808-18. [0124] Fagerstrom K O, Heatherton T F, Kozlowski L T. Nicotine addiction and its assessment. Ear, nose, & throat journal. 1990; 69(11):763-5. [0125] Gritz E R, Carr C R, Marcus A C. The tobacco withdrawal syndrome in unaided quitters. British journal of addiction. 1991; 86(1):57-69. [0126] Hughes J R. Tobacco withdrawal in self-quitters. Journal of consulting and clinical psychology. 1992; 60(5):689-97. [0127] Javors M A, Hatch J P, Lamb R J. Sequential combination of self-report, breath carbon monoxide, and saliva cotinine to assess smoking status. Drug and alcohol dependence. 2011; 113(2-3):242-4. [0128] Kotz D, Brown J, West R. Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking. Drug and alcohol dependence. 2013; 128(1-2):15-9. [0129] Prapavessis H, Cameron L, Baldi J C, Robinson S, Borrie K, Harper T, et al. The effects of exercise and nicotine replacement therapy on smoking rates in women. Addictive behaviors. 2007; 32(7):1416-32. [0130] Rohleder N, Kirschbaum C. The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. International journal of psychophysiology: official journal of the International Organization of Psychophysiology. 2006; 59(3):236-43. [0131] Toll B A, Katulak N A, Williams-Piehota P, O'Malley S. Validation of a scale for the assessment of food cravings among smokers. Appetite. 2008; 50(1):25-32. [0132] West R. Mood and Physical Symptoms Scale 2012. Available from the NCSCT (National Centre for Smoking Cessation and Training) website.

[0133] Further Aspects of the Invention:

[0134] 1. Use of a probiotic composition comprising at least one bacterial strain belonging to a Lactobacillus species, a Bifidobacterium species, or a mixture thereof for alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine in an individual in need thereof.

[0135] 2. The use of paragraph 1, wherein said probiotic composition comprises at least one bacterial strain belonging to Lactobacillus species and Bifidobacterium species.

[0136] 3. The use of paragraph 1 or 2, wherein said at least one bacterial strain of Lactobacillus belongs to the species L. acidophilus, L. brevis, L. bulgaricus, L. casei, L. crispatus, L. delbrueckii, L. fermentum, L. gasseri, L. helveticus, L. lactis, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius or L. paracasei, optionally, said at least one bacterial strain of Lactobacillus belongs to the species L. rhamnosus.

[0137] 4. The use of any one of paragraphs 1 to 3, wherein said at least one bacterial strain of Lactobacillus species is L. acidophilus HA-122 (Lallemand Health Solutions (LHS)), L. acidophilus R0418 (LHS), L. brevis HA-112 (LHS), L. casei HA-108 (LHS), L. casei R0215 (LHS), L. delbrueckii bulgaricus HA-137 (LHS), L. fermentum HA-179 (LHS), L. helveticus HA-128 (LHS), L. helveticus HA-501 (LHS), L. helveticus R0052 (LHS), L. helveticus Lafti L10 R0419 (LHS), L. paracasei HA-196 (LHS), L. paracasei HA-274 (LHS), L. paracasei Lafti L26 R0422 (LHS), L. plantarum R0403 (LHS), L. plantarum R0202 (LHS), L. plantarum R1012 (LHS), L. reuteri HA-188 (LHS), L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0011 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS), L. rhamnosus R1039 (LHS), L. salivarius HA-118 (LHS), L. salivarius R0078 (LHS), L. bulgaricus R0440 (LHS) or L. lactis R1087 (LHS).

[0138] 5. The use of any one of paragraphs 1 to 4, wherein said at least one bacterial strain of Bifidobacterium belongs to the species B. bifidum, B. animalis subsp. lactis, B. breve, B. longum, or B. longum subsp. infantis, preferably said at least one bacterial strain of Bifidobacterium belongs to the species B. bifidum or B. longum.

[0139] 6. The use of paragraph 5, wherein said at least one bacterial strain of Bifidobacterium species is B. bifidum HA-132 (LHS), B. bifidum R0071 (LHS), B. breve HA-129 (LHS), B. breve R0070 (LHS), B. infantis HA-116 (LHS), B. infantis R0033 (LHS), B. lactis HA-194 (LHS), B. longum HA-135 (LHS), B. longum R0175 (LHS), B. animalis subsp. lactis R0421 (LHS).

[0140] 7. The use of any one of paragraphs 1 to 6, wherein said at least one bacterial strain of Lactobacillus species belongs to the species L. rhamnosus and said at least one bacterial strain of Bifidobacterium belongs to the species B. longum or B. bifidum.

[0141] 8. The use of paragraph 7, wherein said at least one bacterial strain is L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0011 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS), L. rhamnosus R1039 (LHS), B. longum HA-135 (LHS), B. longum R0175 (LHS), B. bifidum HA-132 (LHS) or B. bifidum R0071 (LHS).

[0142] 9. The use of any one of paragraphs 1 to 8, wherein said at least one bacterial strain of belonging to Lactobacillus species, Bifidobacterium species, or a mixture thereof are for use at a dosage of from about 110.sup.5 to 110.sup.12 cfu total bacteria per dose, from about 110.sup.6 to 110.sup.11 cfu total bacteria per dose, from about 110.sup.7 to 110.sup.10 cfu total bacteria per dose or from about 110.sup.8 to 110.sup.10 cfu total bacteria cfu per dose.

[0143] 10. The use of any one of paragraphs 1 to 9, further comprising the use of a nicotine replacement therapy, optionally wherein said nicotine replacement therapy is a gum, a transdermal patch, a nasal spray, an inhaler, an oral spray or a sublingual tablets/lozenges.

[0144] 11. The use of any one of paragraphs 1 to 10, wherein the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine comprise depression, irritability, anxiety, restlessness, hunger, lack of concentration, insomnia, nervous tremor, light-headedness or craving for tobacco or nicotine.

[0145] 12. A composition comprising at least one bacterial strain belonging to a Lactobacillus species, a Bifidobacterium species, or a mixture thereof for alleviating or suppressing the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine in an individual in need thereof.

[0146] 13. The composition of paragraph 12, wherein said composition comprises at least one bacterial strain belonging to a Lactobacillus species and said at least one bacterial strain of Bifidobacterium belonging to the species B. longum or B. bifidum,

[0147] 14. The composition of paragraph 12, wherein said composition comprises at least one bacterial strain of L. rhamnosus, B. longum and B. bifidum. The composition of any one of paragraphs 12 to 14, wherein said at least one bacterial strain is L. rhamnosus HA-114 (LHS), L. rhamnosus HA-500 (LHS), L. rhamnosus R0011 (LHS), L. rhamnosus R0049 (LHS), L. rhamnosus R0343 (LHS), L. rhamnosus R1039 (LHS), B. longum HA-135 (LHS), B. longum R0175 (LHS), B. bifidum HA-132 (LHS) or B. bifidum R0071 (LHS).

[0148] 15. The composition of any one of paragraphs 12 to 15, further comprising the use of a nicotine replacement therapy, optionally wherein said nicotine replacement therapy is a gum, a transdermal patch, a nasal spray, an inhaler, an oral spray or a sublingual tablets/lozenges.

[0149] 16. The composition of any one of paragraphs 12 to 16, wherein the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine comprise depression, irritability, anxiety, restlessness, hunger, lack of concentration, insomnia, nervous tremor, light-headedness or craving for tobacco or nicotine.